Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Ligand Pharmaceuticals |
---|---|
Information provided by: | Ligand Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00621894 |
The purpose of this study is to assess the ability of LGD-4665 given daily by mouth to increase platelet counts in the treatment of patients with ITP (immune thrombocytopenic purpura). LGD-4665 increased platelet counts safely and tolerably compared to placebo in healthy volunteers. This study will examine the safety, tolerability and efficacy of 7.5 mg capsules of LGD-4665 to increase platelets compared to placebo, randomized 2:1, during blinded treatment for 6 weeks. Evaluation of platelet counts, bleeding scores and safety parameters will be done weekly. All patients are eligible to continue on active, open LGD-4665 treatment for an additional 12 weeks with optimal adjustment of dose for each patient.
Condition | Intervention | Phase |
---|---|---|
Immune Thrombocytopenic Purpura |
Drug: LGD-4665 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension |
Estimated Enrollment: | 24 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
LGD-4665: Experimental Thrombopoietin mimetic
|
Drug: LGD-4665
LGD-4665 Thrombopoietin mimetic
|
2: Placebo Comparator |
Drug: Placebo
Placebo
|
This is a Phase IIA study with two parts to the design.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Laboratory results within normal range except for the following analytes
Exclusion criteria:
Listed medications dosed within:
4 weeks of the first dose of the study treatment:
2 weeks of the first dose of the study treatment:
1 week of the first dose of the study treatment:
3 days of the first dose of the study treatment
United States, California | |
University of California San Diego Medical Center | |
San Diego, California, United States, 92103-8409 | |
University of California, San Francisco | |
San Francisco, California, United States, 94143-1270 | |
United States, Connecticut | |
Davis, Posteraro and Wasser, MD's LLP | |
Manchester, Connecticut, United States, 06040 | |
United States, Florida | |
Baptist Cancer Institute | |
Jacksonville, Florida, United States, 32207 | |
Cancer Center of Florida | |
Orlando, Florida, United States, 32806 | |
United States, Georgia | |
Georgia Cancer Specialists | |
Atlanta, Georgia, United States, 30341 | |
United States, Michigan | |
Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC | |
Detroit, Michigan, United States, 48201 | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 | |
United States, Missouri | |
Washington University School of Medicine - St Louis, MO | |
St. Louis, Missouri, United States, 63110 | |
United States, New Mexico | |
New Mexico Oncology Hematology Consultants | |
Albuquerque, New Mexico, United States, 87109 | |
United States, New York | |
Mount Sinai School of Medicine | |
New York, New York, United States, 10029 | |
Joan and Sanford I. Weill Medical College, Cornell University | |
New York, New York, United States, 10021 | |
United States, Ohio | |
Cleveland Clinic Foundation, Univ. of Ohio | |
Cleveland, Ohio, United States, 44195 | |
Case Western Reserve University School of Medicine | |
Cleveland, Ohio, United States, 44106-7284 | |
United States, Texas | |
Hematology Oncology Associates of South Texas | |
San Antonio, Texas, United States, 78229 |
Principal Investigator: | James Bussel, M.D. | Joan and Sanford I. Weill Medical College, Cornell University |
Responsible Party: | Ligand Pharmaceuticals ( Victor Stevens, Ph.D, Director of Clinical Research ) |
Study ID Numbers: | L4665-03 |
Study First Received: | February 12, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00621894 History of Changes |
Health Authority: | United States: Food and Drug Administration |
ITP Immune thrombocytopenic purpura thrombopoietin mimetic |
oral Ph II Patients diagnosed with ITP who have had one or more prior treatments and are thrombocytopenic with platelet counts < 30,000/µL |
Purpura Thrombocytopathy Signs and Symptoms Thrombocytopenia Hematologic Diseases |
Blood Platelet Disorders Blood Coagulation Disorders Hemostatic Disorders Purpura, Thrombocytopenic |
Purpura Signs and Symptoms Skin Manifestations Thrombocytopenia Immune System Diseases |
Hematologic Diseases Blood Platelet Disorders Blood Coagulation Disorders Purpura, Thrombocytopenic |